STEVIA-DERIVED MOLECULES, METHODS OF OBTAINING SUCH MOLECULES, AND USES OF THE SAME

Abstract

A purified composition of steviol glycoside molecules is described. The composition imparts desirable taste, flavor and flavor modifying properties to food, beverages, and other consumable products.

Claims

1. A stevia-derived composition having taste imparting properties, flavor modifying properties, or a combination thereof, at a purity level of greater than 80%, comprising one or more molecules selected from the group consisting of: ##STR00001## ##STR00002## ##STR00003## ##STR00004## ##STR00005## ##STR00006## ##STR00007## ##STR00008## ##STR00009## ##STR00010##

2. A food, beverage, nutraceutical, pharmaceutical or other consumable product comprising the stevia-derived composition of claim 1.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIG. 1 shows a representative analytical chromatogram of stevia extract A95 using Gradient KM7. The top and middle plots are MS TIC(−) (mass spectrometry total ion current) chromatograms, and the bottom plot is an ELSD (evaporative light scattering detector) chromatogram.

[0013] FIG. 2 is a chart of the schematic steps used to isolate different compounds listed in Table 1.

[0014] FIG. 3 is a chart of the schematic steps used to isolate different compounds listed in Table 1.

[0015] FIG. 4 shows the structure of RSG1 (Related Steviol Glycoside 1).

[0016] FIG. 5 shows the structure of RSG2 (Related Steviol Glycoside 2).

[0017] FIG. 6 shows the structure of RSG3 (Related Steviol Glycoside 3).

[0018] FIG. 7 shows the structure of RSG4 (Related Steviol Glycoside 4).

[0019] FIG. 8 shows the structure of RSG5 (Related Steviol Glycoside 5).

[0020] FIG. 9 shows the structure of RSG6 (Related Steviol Glycoside 6).

[0021] FIG. 10 shows the structure of Rebaudioside T.

[0022] FIG. 11 shows the structure of Rebaudioside Y.

[0023] FIG. 12 shows the structure of Rebaudioside O2.

[0024] FIG. 13 shows the structure of Rebaudioside C2.

[0025] FIG. 14 shows the structure of Rebaudioside W.

[0026] FIG. 15 shows the structure of Rebaudioside W2.

[0027] FIG. 16 shows the structure of Rebaudioside U2.

[0028] FIG. 17A shows an RP-HPLC analysis of selected fractions of stevia leaf extract.

[0029] FIG. 17B shows ELSD and MS analysis of selected fractions of stevia leaf extract.

[0030] FIG. 17C shows .sup.1H-NMR analysis of selected fractions of stevia leaf extract.

[0031] FIG. 17D shows the structure of Rebaudioside W3.

[0032] FIG. 18 shows the structure of Rebaudioside V.

[0033] FIG. 19 shows the structure of Rebaudioside U.

[0034] FIG. 20 shows the structure of Rebaudioside K2.

[0035] FIG. 21 shows the structure of Rebaudioside V2.

DETAILED DESCRIPTION

[0036] The chemical structures of certain of the stevia-derived molecules of the present invention are shown in the Figures appended hereto. As used herein, “stevia-derived molecules” shall refer to molecules obtained from any part of the plants of any variety of the species Stevia rebaudiana.

[0037] These stevia-derived molecules are useful in the preparation of food, beverages, nutraceuticals, pharmaceuticals, tobacco products, cosmetics, oral hygiene products, and the like. Some of the stevia-derived molecules have a steviol backbone, and may be referred to as steviol glycosides. Other stevia-derived molecules of this invention have a different backbone, but may have properties similar to steviol glycosides, or may have other beneficial properties.

[0038] These stevia-derived molecules can be used alone or in combination with other ingredients, such as sweeteners, flavors, flavor modifiers, and the like. Such other ingredients may include steviol glycoside ingredients, or ingredients from other natural or synthetic sources.

[0039] Methods of obtaining stevia-derived molecules include the methods used to extract steviol glycosides from Stevia plant leaves. Other methods may include extraction from other parts of the plant, or other extraction techniques and solvents.

[0040] The following Example demonstrates certain embodiments of the invention, and is not intended to limit the scope of the invention in any way.

Example 1

[0041] A stevia extract available from PureCircle USA Inc. of Oak Brook, Ill., labeled as “A95”, was used to isolate and characterize major and minor steviol glycoside components using the following analytical methodologies.

1.1 Sample

[0042] Product Name: Stevia leaf extract A95

Batch No.: WIP A95 27A

[0043] Manufacturing date: 2 Apr. 2016

1.2 Analytical LCMS (Liquid Crystal Mass Spectrometry)

[0044] Analytical LCMS was performed on a Shimadzu single quad UPLC-system (see Table 1). Two different gradient systems were applied (see Tables 2a and 2b) which are identical for the first 40 min. Gradient KM7 was used to resolve all compounds including already identified steviol glycosides #25-#29, while gradient ACD1 was faster and used for the analysis of compounds #1-#24.

Reference samples were prepared by dissolving Stevia leaf extract A95 (20 mg) in a 1:1 mixture of methanol and dimethyl sulfoxide (DMSO). Sonification for 30 min was necessary to achieve a homogenous solution. The solution was stored at 4° C.
The analytical system proved to be very sensitive towards changes in solvent composition and retention time shifts were observed when a new batch of solvents was used. Therefore, reference samples were analyzed before and after every analytical batch and the assignment of retention times was verified.
A typical analytical chromatogram using gradient KM7 is shown in FIG. 1.

TABLE-US-00001 TABLE 1 LCMS system HPLC System Shimadzu LC-30AD, prominence Interface Shimadzu CBM-20A Degasser Shimadzu DGU-20A5 Autosampler Shimadzu SIL-30AC, prominence Column oven Shimadzu CTO-20AC MS Shimadzu 2020 Single quadrupole DAD Shimadzu SPD-M20A ELSD Sedere ELSD-LT II, Sedex 85 Stationary Phase Agilent Poroshell 120 SB-C18 2.7 μm, 4.6 × 150 mm Flow Rate 0.5 mL/min Mobile Phase: A: Water, 25% Acetonitrile, 0.2% Acetic acid B: Acetonitrile

TABLE-US-00002 TABLE 2 LCMS Gradients Gradient Time A B Flow KM7 [min] [%] [%] [ml/min] 00.00 100 0 0.5 24.00 100 0 0.5 50.00 90 10 0.5 51.00 0 100 0.5 55.00 0 100 0.5 56.00 100 0 0.5 56.01 100 0 1.0 65.00 100 0 0.5 70.00 100 0 0 Gradient Time A B Flow ACD1 [min] [%] [%] [ml/min] 00.00 100 0 0.5 24.00 100 0 0.5 40.00 94.6 5.4 0.5 41.00 0 100 0.5 45.00 0 100 0.5 46.00 100 0 0.5 46.01 100 0 1.0 55.00 100 0 0.5 60.00 100 0 0

1.3 Recrystallisation

[0045] Stevia leaf extract A95 (100 g, white powder) were dissolved in ethanol/water 70/30 (750 mL) at a temperature of 65° C.

The milky solution was allowed to cool down to room temperature in a water bath and then filtrated through a suction filter. The collected crystals were washed with ethanol, dried and stored. Mother liquor and wash solution were kept separate and the respective solvent was removed under vacuum.

1.4 Reversed Phase MPLC (Medium Pressure Liquid Chromatography)

[0046] The respective sample (15 g) is dissolved in methanol, celite (30 g) is added and the solvent removed by a rotary evaporator. The immobilized sample is transferred into a glass column and built into the MPLC system described in Table 3. A time based fractionation leads to 18 fractions (4 min each). Solvents and gradients are described in Table 3.

TABLE-US-00003 TABLE 3 MPLC-System and gradients Pump System Interface Module SCPA Fraction collector Labomatic Labocol Vario 2000 plus Stationary Phase Polygoprep C18, 50-60 μm, glas column 50 × 250 mm Mobile A: Water C: Methanol Phase: B: Aceton D: 2-Propanol Time [min] A [%] B [%] C [%] D [%] Flow [ml/min] Gradient 00.00 85 15 0 0 90 A 51.00 65 35 0 0 90 56.00 0 0 100 0 90 61.00 0 0 0 100 90 Mobile A: Water C: Methanol Phase: B: Methanol D: 2-Propanol Time [min] A [%] B [%] C [%] D [%] Flow [ml/min] Gradient 00.00 75 25 0 0 90 B 51.00 50 50 0 0 90 56.00 0 0 100 0 90 61.00 0 0 0 100 90

1.5 Normal Phase Chromatography

[0047] The respective sample (20 g) is dissolved in methanol, silica (40 g) is added and the solvent removed by a rotary evaporator. The immobilized sample is transferred into a glass column and built into the high pressure liquid chromatography (HPLC) system described in Table 4. Air is removed from the transfer column by washing with Ethyl acetate/methanol 1:1. A time based fractionation leads to 90 fractions (0.5 min each) which are combined based on the UV and ELSD data generated during fractionation. Resulting fractions are analyzed by LCMS. Solvents and gradients are described in Table 4.

TABLE-US-00004 TABLE 4 Preparative HPLC System 2 (HTP-II, NP-Fractionation) HPLC System Knauer K-1800 Autosampler Merck L-7250 UV-detector Knauer ELSD Biotage ELSD-A120 Fraction collector Merck L-7650 Stationary Phase Silica, 50-60 μm Mobile Phase A: Aceton/Ethyl acetate/Water (50/40/10); B: Aceton/Ethyl acetate (85/15) Time A B Flow Gradient A [min] [%] [%] [ml/min] 00.00 100 0 35 372.00 0 100 35

1.6 Reversed Phase HPLC

[0048] The respective sample (up to 3.5 g) is dissolved in methanol, C-18 RP material is added and the solvent removed by a rotary evaporator. The immobilized sample is transferred into a column and built into the HPLC system described in Table 5. A time based fractionation leads to 120 fractions (27 sec each) which are combined based on the UV and ELSD data generated during fractionation. Resulting fractions are analyzed by LCMS. Solvents and gradients are described in Table 5.

TABLE-US-00005 TABLE 5 Preparative HPLC System 3 (SEPbox) HPLC System Sepiatec SEPbox lite UV-detector Merck L-7400 ELSD Sedere Sedex 75 Fraction collector Merck L-7650 Stationary Phase Lichrospher Select B, 10 μm 50 × 250 mm Mobile Phase A: Water, ammonium formate (5 mmol), formic acid, pH 3 B: Methanol/Acetonitril (1/1), ammonium formate (5 mmol), formic acid, pH 3 Delay before fractionation 215 sec Fraction 29 sec Time A B Flow Gradient A [min] [%] [%] [ml/min] 00.00 72 28 80 57.7 46 54 80 58 0 100 80 105 0 100 80 Stationary Phase Kromasil C18, 10 μm 25 × 250 mm Mobile Phase A: Water, ammonium formate (5 mmol), formic acid, pH 3 B: Methanol, ammonium formate (5 mmol), formic acid, pH 3 Delay before fractionation 215 sec Fraction 29 sec Time A B Flow Gradient B [min] [%] [%] [ml/min] 00.00 61 39 30 57.7 43 57 30 58 0 100 30 105 0 100 30 Stationary Phase Lichrospher Select B, 10 μm 50 × 250 mm Mobile Phase A: Water, ammonium formate (5 mmol), formic acid, pH 3 B: Methanol/Acetonitril (1/1), ammonium formate (5 mmol), formic acid, pH 3 Delay before fractionation 215 sec Fraction 29 sec Time A B Flow Gradient C [min] [%] [%] [ml/min] 00.00 70 30 80 57.7 62 38 80 58 0 100 80 105 0 100 80 Stationary Phase Lichrospher Select B, 10 μm 50 × 250 mm Mobile Phase A: Water, ammonium formate (5 mmol), formic acid, pH 3 B: Methanol/Acetonitril (1/1), ammonium formate (5 mmol), formic acid, pH 3 215 sec Delay before fractionation 215 sec Fraction 29 sec Time A B Flow Gradient D [min] [%] [%] [ml/min] 00.00 68 32 80 57.7 53 47 80 58 0 100 80 105 0 100 80 Stationary Phase Kromasil C18, 10 μm 50 × 250 mm Mobile Phase A: Water, formic acid 0.1%, pH 3 B: Acetonitril, formic acid 0.1%, pH 3 Delay before fractionation 180 sec Fraction 22 sec Time A B Flow Gradient E [min.sec] [%] [%] [ml/min] 00.00 76 24 109 40.50 70 30 109 41.00 0 100 109 45.00 0 100 109 Stationary Phase Kromasil C18, 10 μm 25 × 250 mm Mobile Phase A: Water, ammonium formate (5 mmol), formic acid, pH 3 B: Methanol, ammonium formate (5 mmol), formic acid, pH 3 Delay before fractionation 180 sec Fraction 22 sec Time A B Flow Gradient F [min] [%] [%] [ml/min] 00.00 46 54 47 40.50 38 62 47 41.00 0 100 47 45.00 0 100 47 Stationary Phase Lichrospher Select B, 10 μm 50 × 250 mm Mobile Phase A: Water, ammonium formate (5 mmol), formic acid, pH 3 B: Methanol/Acetonitril (1/1), ammonium formate (5 mmol), formic acid, pH 3 Delay before fractionation 215 sec Fraction 29 sec Time A B Flow Gradient G [min] [%] [%] [ml/min] 00.00 70 30 80 57.7 55 45 80 58 0 100 80 105 0 100 80 Stationary Phase Kromasil C18, 10 μm 25 × 250 mm Mobile Phase A: Water, ammonium formate (5 mmol), formic acid, pH 3 B: Methanol, ammonium formate (5 mmol), formic acid, pH 3 Delay before fractionation 180 sec Fraction 22 sec Time A B Flow Gradient H [min] [%] [%] [ml/min] 00.00 50 50 47 40.50 49 61 47 41.00 0 100 47 45.00 0 100 47 Stationary Phase Kromasil C18, 10 μm 50 × 250 mm Mobile Phase A: Water, formic acid 0.1%, pH 3 B: Acetonitril, formic acid 0.1%, pH 3 Delay before fractionation 180 sec Fraction 22 sec Time A B Flow Gradient K [min.sec] [%] [%] [ml/min] 00.00 78 22 109 40.50 68 32 109 41.00 0 100 109 45.00 0 100 109 Stationary Phase Kromasil C18, 10 μm 50 × 250 mm Mobile Phase A: Water, formic acid 0.1%, pH 3 B: Acetonitril, formic acid 0.1%, pH 3 Delay before fractionation 180 sec Fraction 22 sec Time A B Flow Gradient L [min.sec] [%] [%] [ml/min] 00.00 75 25 109 40.50 68 32 109 41.00 0 100 109 45.00 0 100 109

1.7 HILIC (Hydrophilic Interaction Liquid Chromatography)

[0049] The respective sample is dissolved in 2 mL of a 3:1 mixture of solvents A and B (see Table 6). Sample Injection takes place after 9.95 min. A time based fractionation leads to 96 fractions (43 sec each, starting after 18 min) which are combined based on the UV and ELSD data generated during fractionation. Resulting fractions are analyzed by LCMS. Solvents and gradients are described in Table 6.

TABLE-US-00006 TABLE 6 Preparative HPLC System 1 (HTP-I, HILIC-Fractionation) HPLC System Knauer K-1800 Autosampler Merck L-7250 UV-detector Knauer ELSD ELSD Sedex 75 Fraction collector Merck L-7650 Stationary Phase Kromasil 60-10-HILIC-D 50 × 250 mm Flow Rate 80 mL/min Mobile Phase: A: Acetonitril; 0.1% Acetic acid; B: Methanol/Water/Acetic acid (95/4.9/0.1) Flow Gradient Time [min] % A % B [ml/min] 00.00 75 25 80 11.50 75 25 80 65.00 65 35 80 70.00 0 100 80 75.00 0 100 80

1.8 NMR (Nuclear Magnetic Resonance)

[0050] Isolated compounds were identified by NMR spectroscopy using a Bruker 500 Mhz NMR spectrometer. Identification of the aglycon was based on reference .sup.1H-NMR spectra using C17, C18 and C20 proton signals as primary indicators. Especially C20 proton shifts indicated alterations as seen in compounds #4 and #18. Glycosides were elucidated using H-H-Cosy, HSQC and HMBC and experiments using spectra of literature known steviosides as reference.

1.9 Results

[0051] FIG. 1 shows the HPLC chart containing the major peaks identified in Table 7 by using analytical methodology as described above. The schematic steps to isolate different compounds in Table 7 are shown in FIG. 2 and FIG. 3.

TABLE-US-00007 TABLE 7 Formula KM7 Peak (based on Trivial tr Base Peak Fraction Identifier structure) Formula (min) Mass ID MW #1 C.sub.21H.sub.30O.sub.11 6.97 517.3 C-2314-B-07 458 #2 C.sub.44H.sub.70O.sub.24 6.99 981.4 C-2293-E-02_NF2 982 #3 C.sub.32H.sub.52O.sub.15 7.32 735.4 C-2283-C-07_NF2 676 #4 C.sub.50H.sub.80O.sub.28 7.64 1127.4 C-2374-I-05 1128 #5 C.sub.44H.sub.70O.sub.24 8.56 981.4 C-2314-B-12 982 #6 C.sub.50H.sub.80O.sub.28 SvGal1G4 8.95 1127.5 C-2376-E-09 1128 ACD1 965.1 C-2387-K 966 ACD2 C.sub.55H.sub.88O.sub.32 SvA1G5 1259.5 C-2376-E-12 1260 ACD14 C.sub.62H.sub.100O.sub.37 SvR1G6 C-2376-E-15 1436 #7 REB E C.sub.44H.sub.70O.sub.23 SvG4 10.37 965.1 C-2321-E-E09 966 #8 REB O C.sub.52H.sub.100O.sub.37 SvR1G6 11.45 1435.0 C-2348-G-04 1436 #9 REB D C.sub.50H.sub.80O.sub.28 SvG5 12.16 1127.1 C-2340-N-A01 1128 #10 REB K C.sub.50H.sub.80O.sub.27 SvR1G4 12.69 1111.1 C-2293-E-07_NF2 1112 #11 REB N C.sub.56H.sub.90O.sub.32 SvR1G5 13.19 1273.1 C-2321-I-04 1274 #12 REB M C.sub.56H.sub.90O.sub.33 SvG6 15.22 1289.5 C-2340-N-12 1291 #13 C.sub.44H.sub.70O.sub.22 SvR1G3 15.79 949.2 C-2353-K-03 950 #14 REB J C.sub.50H.sub.80O.sub.27 SvR1G4 16.46 1111.1 C-2340-N-03 1112 #15 C.sub.49H.sub.78O.sub.27 SvA1G4 17.93 1097.1 C-2353-K-05 1098 #16 18.31 1289.4 #17b C.sub.49H.sub.78O.sub.27 SvA1G4 1097.5 C-2376-D-09 1098 #17a C.sub.49H.sub.78O.sub.27 SvX1G4 18.80 1097.5 C-2376-B-02 1098 #18 C.sub.44H.sub.70O.sub.23 19.49 965.2 C-2376-D-03 966 #19 C.sub.49H.sub.78O.sub.27 SvA1G4 20.26 1097.4 C-2348-F-11 1098 ACD6 C.sub.55H.sub.88O.sub.32 SvX1G5 20.95 1259.6 C-2374-D-10 1260 #20 C.sub.49H.sub.78O.sub.27 SvXG4 21.14 1097.4 C-2283-F-11_NF2 1098 #21 C.sub.50H.sub.80O.sub.27 SvR1G4 23.31 1111.4 C-2374-D-07 1112 #22 C.sub.55H.sub.88O.sub.32 SvX1G5 25.51 1259.6 C-2283-F-14_NF2 1260 #23 REB H C.sub.50H.sub.80O.sub.27 SvR1G4 30.71 1111.5 C-2321-F-08_NF2 1112 #24 32.14 1111.5 #25 REB I SvG5 37.49 1127.5 #26 REB A C.sub.44H.sub.70O.sub.23 SvG4 40.32 965.1 966 #27 Stevioside SvG3 40.53 641.3 #28 REB C C.sub.44H.sub.70O.sub.22 SvR1G3 50.17 949.5 950 #29 REB B C.sub.38H.sub.60O.sub.18 SvG3 53.76 803.5 C-2321-B-22 804

[0052] A list of novel stevia-leaf-derived molecules isolated by using the method of Example 1 is shown in Table 8 and Table 9.

TABLE-US-00008 TABLE 8 Related Steviol Glycoside Components Related Steviol Glycoside Retention Components Molecular Trivial time (Peak ID) Weight Formula Formula (min) RSG1 (#1) 458 NA C21H30O11 6.97 RSG2 (#2) 982 NA C44H70O24 6.99 RSG3 (#3) 676 NA C32H52O15 7.32 RSG4 (#4) 1128 NA C50H80O28 7.64 RSG5 (#5) 982 NA C44H70O24 8.56

TABLE-US-00009 TABLE 9 Novel Steviol Glycoside Components Steviol Retention Glycoside Molecular Trivial Time (Peak ID) Weight Formula Formula (min) Rebaudioside 1128 SvGal1G4 C50H80O28 8.95 T (#6) Rebaudioside 1260 SvA1G5 C55H88O32 — Y (#ACD 2) Rebaudioside 1436 SvR1G6 C52H100O37 — O2 (#ACD 14) Rebaudioside 950 SvR1G3 C44H70O22 15.79 C2 (#13) Rebaudioside 1098 SvA1G4 C49H78O27 17.93 W (#15) Rebaudioside 1098 SvA1G4 C49H78O27 NA W2 (#17b) Rebaudioside 1098 SvX1G4 C49H78O27 18.8 U2 (#17a) Rebaudioside 1098 SvA1G4 C49H78O27 20.26 W3 (#19) Rebaudioside 1260 SvX1G5 C55H88O32 20.95 V (#ACD6) Rebaudioside 1098 SvX1G4 C49H78O27 21.14 U (#20) Rebaudioside 1112 SvR1G4 C50H80O27 23.31 K2 (#21) Rebaudioside 1260 SvX1G5 C55H88O32 25.51 V2 (#22)

Example 2: Identification and Characterization of a Novel Compound

[0053] This Example outlines the isolation, identification and characterization of Rebaudioside W3 (#19) as an example. Similar analysis was carried out for all novel steviol glycoside molecules.

Isolation

[0054] 100 g stevia leaf extract A95 were recrystallized according to the method described in section 1.3 (Example 1) yielding 33.2 g of enriched minor compounds from mother liquor. The enriched minor compounds were fractionated using normal phase chromatography as described in section 1.5 using gradient A (see Table 4). Fractions 49-60 yielded 1.32 g of enriched minor compounds which were further fractionated using reversed phase HPLC according to section 1.4 using gradient L.

RP (Reversed Phase)—HPLC & LCMS

[0055] Fractions 51+52 are marked (FIG. 17A) by a red rectangle, ELSD trace (blue) and UV trace (orange) yielded 37.5 mg of #19. Fractions 66+67 (FIG. 17B) with preparative RP-HPLC chromatogram yielded 3.85 g of enriched minor compounds, Fractions 66+67 were analyzed by LCMS according to section 3.2 (see FIG. 17B). 37.5 mg of compound #19 were obtained with 89% purity (ELSD).

NMR

[0056] The structure of compound #19 was determined by NMR on a 500 MHz Bruker-NMR in d.sub.4-Methanol (δ.sub.C=48.5 ppm; δ.sub.H=3.3 ppm). The data are shown in Table 10 and the NMR analysis is shown in FIG. 17C. The structure of compound #19 is shown in FIG. 17D.

TABLE-US-00010 TABLE 10 Assignment of the .sup.1H-and .sup.13C-NMR-Signals (based on HH-COSY, HSQC, HMBC and HSQC-TOCSY experiments) Position δ.sub.C [ppm] δ.sub.H [ppm] J [Hz]/(INT) HMBC (H -> C) Aglycon moiety  1 40.6 t 0.87 m 1.90 m  2 19.1 t 1.46 m 1.96 m  3 37.4 t 1.56 m 1.98  4 43.5 s —  5 57.5 d 1.15 m  6 21.9 t 1.88 m 2.03  7 41.7 t 1.48 m 1.60 m  8 54.0 s —  9 54.2 d 1.00 m 10 39.0 s — 11 19.6 t 1.67 m 1.80 m 12 38.0 t 1.08 m 2.17 m 13 87.6 s — 14 44.2 t 1.59 d 11.6 2.25 d 11.6 15 47.5 t 2.07 d 15.9 7, 8, 9, 14 2.16 d 15.9 16 152.5 s — 17 104.7 t 4.90 br s 13, 15, 16 5.26 br s 18 27.7 q 1.24 s (3H) 3, 4, 5, 19 19 177.3 s — 20 15.4 d 0.99 s (3H) 1, 5, 9, 10 Sugar moiety β-D-Glucopyranoside  1.sup.i 96.5 d 4.64 d 8.4 13  2.sup.i 79.0 d 3.67 t 8.4  3.sup.i 86.7 d 3.78 t 8.4  4.sup.i 69.6 d 3.38 t 8.4  5.sup.i 77.5 d 3.41 m  6.sup.i 61.7 t 3.68 m 3.93 m β-D-Glucopyranoside  1.sup.ii 103.0 d 4.87 d 8.4 2.sup.i  2.sup.ii 74.8 d 3.23 t 8.4  3.sup.ii 77.1 d 3.29 t 8.4  4.sup.ii 71.2 d 3.19 t 8.4  5.sup.ii 77.1 d 3.26 m  6.sup.ii 61.8 t 3.66 m 3.89 m β-D-Glucopyranoside  1.sup.iii 103.4 d 4.70 d 8.4 3.sup.i  2.sup.iii 74.5 d 3.30 t 8.4  3.sup.iii 77.3 d 3.33 t 8.4  4.sup.iii 70.2 d 3.28 t 8.4  5.sup.iii 76.7 d 3.35 m  6.sup.iii 61.3 t 3.67 m 3.88 m β-D-Glucopyranoside  1.sup.iv 94.5 d 5.40 d 8.4 19  2.sup.iv 73.2 d 3.37 t 8.4  3.sup.iv 77.5 d 3.47 t 8.4  4.sup.iv 69.7 d 3.45 t 8.4  5.sup.iv 76.6 d 3.58 m  6.sup.iv 67.9 t 3.86 m 4.09 m β-D-Arabinopyranoside  1.sup.v 103.7 d 4.33 d 8.4  6.sup.iv  2.sup.v 71.5 d 3.60 t  3.sup.v 73.0 d 3.58 t  4.sup.v 68.5 d 3.83 br s  5.sup.v 65.5 d 3.53 m 3.89 m

[0057] Each of these minor molecules identified above, preferably at purity levels ranging from 80-99%, including 90-95% purity, 99% purity, and 89% purity and higher, either as isolated or in combination with other stevia-derived molecules, are believed to have numerous desirable effects on the sweetness, taste and flavor profiles of products containing stevia-based ingredients. These molecules can be useful in imparting specific tastes or modifying flavors, or both, in food, beverage, nutraceutical, pharmaceutical, and other comestible or consumable products.

[0058] It is to be understood that the foregoing description and specific embodiments shown herein are merely illustrative of the best mode of the invention and the principles thereof, and that modifications and additions may be easily made by those skilled in the art without departing for the spirit and scope of the invention, which is therefore understood to be limited only by the scope of the appended claims.